摘要
采用前瞻性、多中心、随机、单盲、平行对照的方法,将符合ARA诊断标准的226例类风湿关节炎患者分为2组。治疗组114例,采用雷公藤缓释片(TW-SR)治疗,每次2片,每天2次,连服4周;对照组112例采用雷公藤片(TW)治疗,每次2片,每天3次,连服4周。结果表明:,总有效率TW-SR和TW分别为92.11%和90.65%(P>0.05);不良反应率TW-SR和TW分别为20.18%和70.54%(P<0.01)。临床前药理实验研究结果表明:TW-SR与TW一样具有显著的抗炎、镇痛和免疫抑制作用。TW-SR毒性明显小于TW。
Adopt to the prospective, multi-center, random, single-blind, equal rank-control methods, 226 patients of rheumatoid arthritis diagnosed according to the ARA criteria, were divided into 2 groups. One hundred and fourteen patients of test group were treated with sustained release tablets of Triptergium wilfordii (TW-SR) orally, 2 tablets, twice a day for 4 weeks, 112 patients of control group received tablets of Tripterygium wilfordii (TW) orally, 2 tablets 3 times per day for 4 weeks.Results showed that the total effective rate of the two groups were 92. 11 % and 90. 65%, respectively (P >0. 05).The adverse reaction rate of TW-SR group was 20. 18%, which was lowered than that of TW group (70 . 54%,P < 0 . 01 ) . Results of pre-clinical pharmacologic experimental study showed that the TW-SR has obvious anti-inflammatory,analgesia and immunosuppress'ive action as the TW has, while its toxicity was less than the latter significantly.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
1996年第1期10-13,共4页
Chinese Journal of Integrated Traditional and Western Medicine
关键词
类风湿关节炎
雷公藤
雷公藤缓释片
rheunmatoid arthritis, Tripterygium wilfordii, sustained-release tablet